000 | 01968 a2200565 4500 | ||
---|---|---|---|
005 | 20250516135908.0 | ||
264 | 0 | _c20130510 | |
008 | 201305s 0 0 eng d | ||
022 | _a1474-4457 | ||
024 | 7 |
_a10.1016/S1473-3099(13)70005-7 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBejon, Philip | |
245 | 0 | 0 |
_aEfficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. _h[electronic resource] |
260 |
_bThe Lancet. Infectious diseases _cApr 2013 |
||
300 |
_a319-27 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
650 | 0 | 4 |
_aAfrica _xepidemiology |
650 | 0 | 4 | _aChild |
650 | 0 | 4 | _aChild, Preschool |
650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
650 | 0 | 4 |
_aDisease Transmission, Infectious _xprevention & control |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aMalaria Vaccines _xadministration & dosage |
650 | 0 | 4 |
_aMalaria, Falciparum _xepidemiology |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMultivariate Analysis |
650 | 0 | 4 |
_aPlasmodium falciparum _ximmunology |
650 | 0 | 4 | _aPoisson Distribution |
650 | 0 | 4 |
_aPrimary Prevention _xmethods |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aVaccination _xmethods |
700 | 1 | _aWhite, Michael T | |
700 | 1 | _aOlotu, Ally | |
700 | 1 | _aBojang, Kalifa | |
700 | 1 | _aLusingu, John P A | |
700 | 1 | _aSalim, Nahya | |
700 | 1 | _aOtsyula, Nekoye N | |
700 | 1 | _aAgnandji, Selidji T | |
700 | 1 | _aAsante, Kwaku Poku | |
700 | 1 | _aOwusu-Agyei, Seth | |
700 | 1 | _aAbdulla, Salim | |
700 | 1 | _aGhani, Azra C | |
773 | 0 |
_tThe Lancet. Infectious diseases _gvol. 13 _gno. 4 _gp. 319-27 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1473-3099(13)70005-7 _zAvailable from publisher's website |
999 |
_c22547019 _d22547019 |